ProUroCare is engaged in the business of developing innovative products for the detection and characterization of male prostate disease. The company s initial product, a prostate mechanical imaging device called the ProUroScan system, was approved by the FDA for commercialization in the United States in April .
Quote | Prourocare Med Inc (OTCMKTS:PUMD)
Last: | $0.0001 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0001 |
Close: | $0.0001 |
High: | $0.0001 |
Low: | $0.0001 |
Volume: | 600 |
Last Trade Date Time: | 10/23/2023 03:00:00 am |
News | Prourocare Med Inc (OTCMKTS:PUMD)
Message Board Posts | Prourocare Med Inc (OTCMKTS:PUMD)
Subject | By | Source | When |
---|---|---|---|
$PUMD SEC Suspension because of questions regarding the | Renee | investorshub | 03/16/2020 1:59:00 PM |
Anyone got an A/S O/S here | zjohns025 | investorshub | 02/16/2020 9:04:15 PM |
$PUMD: She's getting alot of ATTENTION..... AWESOME | makinezmoney | investorshub | 02/23/2018 11:51:59 AM |
She's getting PUMDed......lol | Zardiw | investorshub | 02/23/2018 1:24:59 AM |
$PUMD: Is this now Artann Laboratories ? | makinezmoney | investorshub | 02/22/2018 6:22:34 PM |